Expertise:
Medicinal Chemistry, Drug discovery, Organic Chemistry, Green Chemistry and total synthesis.
Profile:
Dr. Vinod Chaudhari is a Medicinal Chemist, received his PhD in
Synthetic Organic/Carbohydrate Chemistry from University of Pune, Pune and
subsequently moved to University Joseph Furrier (CNRS), Grenoble, France for a
Post-Doctoral training on Synthetic Organic Chemistry. He has over 12 years of
Synthetic and Medicinal Chemistry research experience in Indian Industries. He
has worked at Lupin Research Park Pune, Aurigene Discovery Technology Ltd and
Zydus Research Centre, prior to joining CSIR-IMTECH Jan 2019. Vinod has
experience in leading drug discovery teams that successfully delivered several
preclinical/clinical development candidates. He has experience in working with
various target classes including GPCRs, Ion channels and Kinases, across
different therapeutic areas like Metabolic disorders, Oncology, Respiratory
diseases, Inflammation, and Neurosciences.
At CSIR-IMTECH his research group focus will be on new drug discovery in
the different therapeutic areas like of Oncology, Antimicrobial resistance, Infectious
and Neglected diseases. Currently working on design and synthesis of novel
small molecules targeting different targets for the therapeutic area of
Respiratory infectious diseases particularly tuberculosis (TB), Antimicrobial
resistance (AMR), Virology and Oncology. His research focus is also on total
synthesis of biologically active natural/unnatural products and development of
green methodologies.
Selected Patents
- Substituted tricyclic heterocyclic compounds as metallo-beta-lactamase
inhibitors. WO2022254464A1.
- Arylalkylamine Compounds as Calcium Sensing Receptor Modulators. WO2014/033604, US2015/239827, US2016/075655, US2017/0137371, EP2888225, AU2013/308081, CA2882039, CN104583177, IN421MUN2015, JP2015/528462, HK1211916.
- Substituted Morpholines as Modulators for The Calcium Sensing Receptor. WO2012/120476, US2013/345213, US2016/0250219, EP2683697, AU2012/226375, CA2828415, ZA2013/06576, IN2011KOL31720110310.
- Diaza-spiro[5,5]undecanes as Orexin Receptor Antagonists; WO2011/076747, US2012/2264748, EP2516439, JP2013/515033, AR079553, CN102762567, TW2011/32642, UY33125; Novartis AG, Switzerland.
- Disubstituted Heteroaryl-Fused Pyridines.WO2011/076744, US2012/258973, EP251637, CN102762560, IN2009/02664, JP2013/515032.
- Di/tri-Aza-Spiro-C9-C11 Alkanes. WO2012/101487, US2012/165331, AR084430.
Major Publications
- Diversity in the ligand binding pocket of HapR attributes to its uniqueness towards several inhibitors with respect to other homologues-A structural and molecular perspective. Sen et al; International Journal of Biological Macromolecules, 2023, 233, 12395.
- One-Pot
Domino Reaction: Direct Access to Polysubstituted 1,4- 2 Benzothiazine
1,1-Dioxide via Water-Gas Shift Reaction Utilizing DMF/H2O; Sharma et al. The
Journal of Organic Chemistry, 2023, 88 (1)
- Discovery of a Potent and Selective PI3Kδ Inhibitor (S)-2,4-Diamino-6-((1-(7-fluoro-1-(4-fluorophenyl)-4-oxo-3-phenyl-4H-quinolizin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile with Improved Pharmacokinetic Profile and Superior Efficacy in Hematological Cancer Models. Shukla, M. R., et al.; Journal of Medicinal Chemistry, 2020, 63 (23), 14700.
- Free spermidine evokes superoxide radicals that manifest toxicity. Kumar, V., et al Elife, 2022, 11, e77704.
- Identification of a Novel Series of Orexin Receptor Antagonists with a Distinct Effect on Sleep Architecture for the Treatment of Insomnia. BetschartC., et al; Journal of Medicinal Chemistry, 2013, 56 (19), 7590–7607.
- An Efficient Synthesis of D-erythro- and D-threo-Sphingosine from D-Glucose: Olefin Cross-Metathesis Approach. Chaudhari, V. D., et. al.; Organic Letters,2005, 7, 5805.
Lab Members